Second Amendment to Licensing AgreementLicensing Agreement • May 15th, 2018 • PharmaCyte Biotech, Inc. • Medicinal chemicals & botanical products
This Second Amendment to the Licensing Agreement (“Second Amendment”) is effective on the date the parties have fully signed the Second Amendment (“Effective Date of the Second Amendment”) and memorializes an agreement reached between PharmaCyte Biotech, Inc., formerly Nuvilex, Inc. (“Licensee”), and Austrianova Singapore Pte. Ltd. (“Licensor”) on 30 August 2017 relating to the Licensing Agreement between the Parties dated as of June 25, 2013, as amended by the First Amendment to the Licensing Agreement dated as of 24 June 2016 (collectively, “Licensing Agreement”). Licensee and Licensor are referred to in this Second Amendment individually as a “Party” and collectively as the “Parties.” Defined terms in the Licensing Agreements have the same meaning in this Second Amendment as they do in the Licensing Agreement.
Third Amendment to Licensing AgreementLicensing Agreement • May 15th, 2018 • PharmaCyte Biotech, Inc. • Medicinal chemicals & botanical products
This Third Amendment to the Licensing Agreement (“Third Amendment”) is effective on the date the parties have fully signed the Third Addendum (“Effective Date of the Third Amendment”) and memorializes the agreement reached between PharmaCyte Biotech, Inc., formerly Nuvilex, Inc. (“Licensee”), and Austrianova Singapore Pte Ltd (“Licensor”) on 30 August 2017 relating to the Licensing Agreement between the Parties dated as of 1 December 2014, as amended by the First Amendment to the Licensing Agreement dated as of June 30, 2015 and the Second Amendment to the Licensing Agreement dated as of 19 October 2015 (collectively, “Licensing Agreement”). Licensee and Licensor are referred to in this Third Amendment individually as a “Party” and collectively as the “Parties.” Defined terms in the Licensing Agreement have the same meaning in this Third Amendment as they do in the Licensing Agreement.
Fourth Addendum to Asset Purchase AgreementAsset Purchase Agreement • May 15th, 2018 • PharmaCyte Biotech, Inc. • Medicinal chemicals & botanical products
This Fourth Addendum to Asset Purchase Agreement (“Fourth Addendum”) is effective as on the date the parties have fully signed the Fourth Addendum (“Effective Date of the Fourth Addendum”) and memorializes an agreement reached between PharmaCyte Biotech, Inc., formerly Nuvilex, Inc. (“Licensee”), and SG Austria Pte. Ltd. (“Licensor”) on 30 August 2017, as amended, relating to the Asset Purchase Agreement between the Parties dated as of the 26th day of May 2011 (“Asset Purchase Agreement”), as amended by the Asset Purchase Agreement Addendum dated as of June 11, 2011, the Asset Purchase Agreement Addendum Number 2 dated as of June 14, 2012, the December 3, 2012 extension letter from SG Austria, the Third Addendum to Asset Purchase Agreement dated as of June 25, 2013 (“Third Addendum”) and the Clarification Agreement to Third Addendum to Asset Purchase Agreement dated as of June 25, 2013 (“Clarification Agreement”). Licensee and Licensor are referred to in this Fourth Addendum individual
